С. В. Орлов

14.4k citations
107 papers · 6.9k · 7 hit papers · h-index 28

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers

Papers in

С. В. Орлов

88 papers receiving 6.7k citations

С. В. Орлов's Hit Papers

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer 2017 · 254 citations
2540+6+13Years since publication50010001.5k2.0k2.5k

Peers

С. В. Орлов
Comparison fields: 5 of 126
  • Pulmonary and Respiratory Medicine 4.0k
  • Oncology 2.9k
  • Hepatology 455
  • Cancer Research 788
  • Molecular Biology 1.8k
Replace Farrokh Dehdashti with:
Farrokh Dehdashti United States
Thomas E. Stinchcombe United States
George Sgouros United States
Hideki Watanabe Japan
Edwin M. Posadas United States
Vassilis Georgoulias Greece
Mechthild Krause Germany
Isamu Okamoto Japan
Howard Safran United States
Eugene J. Koay United States
С. В. Орлов relative to Farrokh Dehdashti United States Farrokh Dehdashti's profile →
Citations per field
00.5×1.5×2.3×
Farrokh Dehdashti · 1×
Citations per year

Countries citing papers authored by С. В. Орлов

Since Specialization
Citations

This map shows the geographic impact of С. В. Орлов's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by С. В. Орлов with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites С. В. Орлов more than expected).

Fields of papers citing papers by С. В. Орлов

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by С. В. Орлов. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by С. В. Орлов. The network helps show where С. В. Орлов may publish in the future.

Co-authors

The 25 scholars most cited alongside С. В. Орлов, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with С. В. Орлов Line = papers co-authored together С. В. Орлов links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 107 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Hit paper breakdown →
20132516
2
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Hit paper breakdown →
2014718
3
Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
Hit paper breakdown →
2006561
4
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Hit paper breakdown →
2013379
5
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
Hit paper breakdown →
2011327
6
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Hit paper breakdown →
2015294
7
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
Hit paper breakdown →
2017254
8 2015219
9 2011154
10 2020121
11 2022101
12 201184
13 200879
14 201078
15 201668
16 201067
17 201450
18 202349
19 197942
20 201740

About С. В. Орлов

С. В. Орлов is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery and Ceramics and Composites, having authored 107 papers that have together received 6.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (11 papers), Colorectal Cancer Treatments and Studies (8 papers), Advanced ceramic materials synthesis (8 papers), Tissue Engineering and Regenerative Medicine (5 papers), Cancer Treatment and Pharmacology (5 papers), Photochemistry and Electron Transfer Studies (5 papers) and Electrospun Nanofibers in Biomedical Applications (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.0k citations), Oncology (2.9k citations), Hepatology (455 citations), Cancer Research (788 citations) and Molecular Biology (1.8k citations). С. В. Орлов has collaborated with scholars based in Russia, United States and Germany. Frequent co-authors include Lecia V. Sequist, Vera Hirsh, В. А. Горбунова, Sarayut Lucien Geater, James Chih‐Hsin Yang, Tony Mok, Wu‐Chou Su, Jaafar Bennouna, Victoria Zazulina and Nobuyuki Yamamoto. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Physics Letters A.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact